Spear Therapeutics

Spear Therapeutics is an early-stage biotechnology company focused on developing a new class of programmable genetic medicines and targeted therapies. Spun out of the Wyss Institute at Harvard University, the company leverages advanced DNA nanotechnology to create proximity-activated therapeutics that can precisely target diseased cells while sparing healthy tissue. The company's technology is based on the same underlying principles as its sister company, Spear Bio, which focuses on ultrasensitive protein detection. Spear Therapeutics is currently in the pre-clinical stage, primarily targeting applications in oncology and complex genetic disorders.